{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T18:37:03Z","timestamp":1761935823540,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1053\/j.seminhematol.2004.02.009","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T13:00:54Z","timestamp":1086786054000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S3","title":["Transplant strategies for idiopathic myelofibrosis"],"prefix":"10.1053","volume":"41","author":[{"given":"John M","family":"McCarty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2004.02.009_BIB1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/asheducation.V2000.1.51.51","article-title":"A polycythemia vera updated","author":"Pearson","year":"2000","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB3","first-page":"264","article-title":"Histopathological trephine biopsy findings in cases of \u2018dry tap\u2019 bone marrow aspirations","volume":"2","author":"Navone","year":"1984","journal-title":"Appl Pathol"},{"issue":"suppl 2","key":"10.1053\/j.seminhematol.2004.02.009_BIB4","first-page":"153","article-title":"Radiography of breast cancers","volume":"4","author":"Willemin","year":"1975","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB5","first-page":"830","article-title":"Bone involvement in chronic myelocytic leukemia","volume":"35","author":"Rudorf","year":"1980","journal-title":"Z Gesamte Inn Med"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ajh.10114","article-title":"Bone marrow necrosis","volume":"70","author":"Paydas","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB7","first-page":"2947","article-title":"Marrow scintigraphy in Paget\u2019s disease of bone (author\u2019s transl)","volume":"7","author":"Mazieres","year":"1978","journal-title":"Nouv Presse Med"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB8","first-page":"405","article-title":"A histomorphometric analysis of heavily loaded and non-loaded implants","volume":"17","author":"De Pauw","year":"2002","journal-title":"Int J Oral Maxillofac Implants"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000205686","article-title":"Primary polycythaemia, essential thrombocythaemia and myelofibrosis\u2014Three facets of a single disease process?","volume":"79","author":"Adams","year":"1988","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/0145-2126(88)90008-2","article-title":"Megakaryocyte colony formation in chronic myeloid leukemia and myelofibrosis","volume":"12","author":"Juvonen","year":"1988","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJM199802263380903","article-title":"Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera","volume":"338","author":"Moliterno","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB12","first-page":"797a","article-title":"Quantification of c-Mpl protein expression and PRV-1 mRNA levels distinguish four distinct subpopulations of patients with ET","volume":"100","author":"Goerttler","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0145-2126(02)00069-3","article-title":"Elevated thrombopoietin levels in patients with myelofibrosis may not be due to enhanced production of thrombopoietin by bone marrow","volume":"27","author":"Wang","year":"2003","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB14","article-title":"Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia","author":"Tefferi","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s002770000278","article-title":"Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis","volume":"80","author":"Thiele","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB16","first-page":"256","article-title":"Idiopathic myelofibrosis with extramedullary hematopoiesis in the kidneys","volume":"52","author":"Schnuelle","year":"1999","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/0268-960X(91)90041-A","article-title":"Idiopathic myelofibrosis","volume":"5","author":"Weinstein","year":"1991","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0268-960X(97)90022-9","article-title":"Idiopathic myelofibrosis","volume":"11","author":"Reilly","year":"1997","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0300-2977(98)00143-0","article-title":"Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis","volume":"54","author":"Michiels","year":"1999","journal-title":"Neth J Med"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/blood.V51.2.189.189","article-title":"Agnogenic myeloid metaplasia","volume":"51","author":"Jacobson","year":"1978","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2141.1994.tb05076.x","article-title":"Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis","volume":"88","author":"Reilly","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1600-0609.1982.tb00602.x","article-title":"Circulating haematopoietic progenitors in myelofibrosis","volume":"29","author":"Partanen","year":"1982","journal-title":"Scand J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00277-001-0417-4","article-title":"CD34+ progenitor cells in idiopathic (primary) myelofibrosis","volume":"81","author":"Thiele","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1034\/j.1600-0609.2002.01610.x","article-title":"Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia","volume":"68","author":"Andreasson","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/10428199709055584","article-title":"Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders","volume":"24","author":"Thiele","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB27","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1073\/pnas.93.17.9126","article-title":"Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor","volume":"93","author":"Kieran","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB28","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1182\/blood.V96.7.2440","article-title":"Biologic significance of GATA-1 activities in Ras-mediated megakaryocytic differentiation of hematopoietic cell lines","volume":"96","author":"Matsumura","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0369-8114(00)00021-3","article-title":"Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis","volume":"49","author":"Bousse-Kerdiles","year":"2001","journal-title":"Pathol Biol (Paris)"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB30","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1182\/blood-2002-02-0485","article-title":"Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors","volume":"100","author":"Giraudier","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB31","first-page":"651","article-title":"Idiopathic myelofibrosis","volume":"109","author":"Cervantes","year":"1997","journal-title":"Med Clin (Barc)"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/(SICI)1096-8652(199902)60:2<130::AID-AJH8>3.0.CO;2-Z","article-title":"Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases","volume":"60","author":"Garcia-Manero","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0165-4608(02)00554-X","article-title":"Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia","volume":"137","author":"Andrieux","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000064708","article-title":"Cytogenetic and molecular genetic aspects of idiopathic myelofibrosis","volume":"108","author":"Reilly","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB35","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1365-2141.1998.00833.x","article-title":"Myelofibrosis with myeloid metaplasia in young individuals","volume":"102","author":"Cervantes","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB37","first-page":"1204","article-title":"Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia","volume":"88","author":"Sagaster","year":"2003","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF01006549","article-title":"Oxymetholone treatment in myelofibrosis","volume":"37","author":"Hast","year":"1978","journal-title":"Blut"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2001.02918.x","article-title":"Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia","volume":"114","author":"Barosi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1385\/MO:19:2:79","article-title":"Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia","volume":"19","author":"Merup","year":"2002","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1034\/j.1600-0609.2002.01669.x","article-title":"Remission of transformed myelodysplastic syndrome with fibrosis after danazol therapy","volume":"68","author":"Damaj","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000203720","article-title":"Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis","volume":"96","author":"Bourantas","year":"1996","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.10431","article-title":"Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis","volume":"74","author":"Hasselbalch","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ajh.2830330210","article-title":"The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia","volume":"33","author":"Benbassat","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB45","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood.V53.3.515.515","article-title":"Splenectomy in myeloid metaplasia","volume":"53","author":"Silverstein","year":"1979","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB46","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2141.1998.00998.x","article-title":"Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia","volume":"103","author":"Elliott","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-2141.1991.tb07989.x","article-title":"Management of myelofibrosis with intermittent hydroxyurea","volume":"77","author":"Manoharan","year":"1991","journal-title":"Br J Haematol"},{"issue":"suppl","key":"10.1053\/j.seminhematol.2004.02.009_BIB48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0609.1990.tb00898.x","article-title":"Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia","volume":"52","author":"Barosi","year":"1990","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB49","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","article-title":"Long term treatment of myeloproliferative disease with interferon-alpha-2b","volume":"83","author":"Gilbert","year":"1998","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB50","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","article-title":"Melphalan treatment in patients with myelofibrosis with myeloid metaplasia","volume":"116","author":"Petti","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB51","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM200103083441016","article-title":"Stem-cell transplantation for myelofibrosis","volume":"344","author":"Deeg","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB52","first-page":"743","article-title":"Allogeneic bone marrow transplantation for primary myelofibrosis","volume":"16","author":"Singhal","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB53","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood.V86.12.4667.bloodjournal86124667","article-title":"Relevance of marrow fibrosis in bone marrow transplantation","volume":"86","author":"Soll","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB54","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2141.1997.3083125.x","article-title":"Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis","volume":"98","author":"Anderson","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB55","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1046\/j.1365-2141.1997.3073124.x","article-title":"Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation","volume":"98","author":"Guardiola","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB56","first-page":"2831","article-title":"Allogeneic stem cell transplantation for agnogenic myeloid metaplasia","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB57","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood.V67.6.1693.1693","article-title":"Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation","volume":"67","author":"Rajantie","year":"1986","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB58","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0369-8114(00)00020-1","article-title":"Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia","volume":"49","author":"Cervantes","year":"2001","journal-title":"Pathol Biol (Paris)"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB59","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB60","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V98.3.586","article-title":"Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis","volume":"98","author":"Anderson","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB61","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","article-title":"Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia","volume":"99","author":"Devine","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB62","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bmt.1704172","article-title":"FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia","volume":"32","author":"Tanner","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB63","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1046\/j.1365-2141.2002.03884.x","article-title":"Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia","volume":"119","author":"Hessling","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB64","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood.V97.7.2180","article-title":"Splenectomy and hemopoietic stem cell transplantation for myelofibrosis","volume":"97","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.009_BIB65","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.leu.2402043","article-title":"Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation","volume":"15","author":"Li","year":"2001","journal-title":"Leukemia"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719630400037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719630400037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:12:37Z","timestamp":1758521557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719630400037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":65,"alternative-id":["S003719630400037X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2004.02.009","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transplant strategies for idiopathic myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2004.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}